ONLINE REGISTRATION IS CLOSED.  YOU CAN REGISTER ONSITE - $50. fee to register at the door.

 

Converting Knowledge from universities into commercial opportunities, innovations, and jobs require networks, interactions, and collaboration between a university and the rest of the ecosystem. This includes investors, entrepreneurs and industrial partners. Join us for a discussion on Technology Transfer were you'll hear an investment perspective regarding the changes and programs recently developed at UConn and Yale. Changes, emerging from their labs,  that are enhancing investment in commercial opportunities.

Panelists: (To present on the topic of co-investment and funding opportunities.)

• Christopher Loose, Professor & Executive Director of CBIT, Yale
• Ali Andalibi, Associate Vice President, UConn
  (Full Bio's featured below)

Pitching Companies (Student teams from UConn and Yale):

UConn Student teams:

• Dura Biotech -  A developer of innovative technologies to improve functionality and durability of bioprosthetic heart valves, in particular, transcatheter heart valves.
• Haptitude SDK - A software platform that enables researcher, developers, and innovators to add the 'sense of touch' into their interactive computer solutions. (Presenting: Morad Behandish, Ph.D. candidate.)

Yale Student Teams:

• Ancera - A next-generation life sciences tools company, capable of providing results from complex samples such as blood and food in as little as 15 minutes. (Presented by: Arjun Ganesan)
• 109 Design - A wearable health technology company dedicated to improving the treatment of scoliosis via a software platform that allows for incentive-based prescriptions and personalized care. 
  

Panelist Bios:

Christopher Loose is the Executive Director of CBIT, while holding appointments at Yale as Assistant Professor Adjunct, Urology and Lecturer, Biomedical Engineering. He is also an Accelerator Executive at the Center for Integration of Medicine and Innovative Technology (CIMIT). In 2006, Dr. Loose co-founded Semprus BioSciences with Massachusetts Institute of Technology (MIT) Institute Professor Robert Langer and David Lucchino, and served as Chief Technology Officer until the company was acquired by Teleflex Incorporated in 2012. A peer-review of the Semprus Technology was published in Science Translational Medicine and received a Frost and Sullivan Breakthrough Technology Award in 2010. Semprus’ first product, a vascular catheter with a surface modification designed to have reduced thrombus (clot) formation, was FDA-cleared in 2012. Loose received the prestigious Hertz Foundation Fellowship and was selected by MIT’s Technology Review as a member of the “TR35,” naming the world's top 35 innovators under the age of 35. He was awarded the inaugural Peter Strauss Entrepreneurial Award from the Hertz Foundation in 2011 and was also named to Boston Business Journal's 40 emerging busing leaders under 40. While earning his PhD. in Chemical Engineering at MIT, Loose co-authored the Semprus Biosciences business plan which won entrepreneurial competitions at MIT, Harvard University and Oxford University. Prior to his graduate work, Loose was a chemical engineer at Merck Research Labs after graduating summa cum laude with a B.S.E in Chemical Engineering from Princeton University.

Ali Andalibi is the Associate Vice President for Research at the University of Connecticut. He came to UConn from Stony Brook University, where he also served as the Associate Vice President for Research and Deputy Operations Manager. Before joining Stony Brook, Andalibi served as the Vice President of Research and Chief Scientific Officer at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center. Previous to that position, he served as a Program Director and head of the Therapeutics and Diagnostics Section in the National Cancer Institute's SBIR Development Center. Prior ro moving to the NCI, Andalibi served as a Program Director in the National Science Foundation's Division of Industrial Innovation and Partnerships, where he oversaw the NSF's medical biotechnology SBIR/STTR grant portfolio. Andalibi joined the NSF from the House Ear Institue (HEI) where he served as the Director of New Technology and Project Development and also held a joint appointment in the Department of Otolaryngology at the University of Southern California, School of Medicine. Andalibi received his PhD from the Department of Microbiology and Molecular Genetics in UCLA and later joined the faculty in the Department of Medicine in UCLA. Subsequently, he was involved in several early stage biotechnology companies before returning to the academe.

 

 

Register Now!